Omri Amirav Drory
InvestorGeneral Partner at NFX · Board director at TwoStep Therapeutics · Board director at ImmuneBridge · Board director at Talus Bio
San Francisco Bay Area
Writes $500K – $5M checks · typically $3M
About
Omri Amirav-Drory is a founder-operator with TechBio lifecycle experience—founding Genome Compiler (acquired by Twist Bioscience), serving as Twist VP of Corporate Development and Innovation and acting as CEO during incubation.
Contact· self-published, not guessed
Invests in
AI & Machine LearningBiotechCrypto & Web3FintechMarketplaces
Board director at TwoStep Therapeutics
Intro paths
In turn, Omri can intro founders to TwoStep Therapeutics's investors below.
TwoStep Therapeutics's investors · 4
Co-founders at TwoStep Therapeutics




Board director at ImmuneBridge
Intro paths
In turn, Omri can intro founders to ImmuneBridge's investors below.
ImmuneBridge's investors · 2
Co-founders at ImmuneBridge
Board director at Talus BioYC S21
Intro paths
Omri went through Y Combinator (Summer 2021) — any YC alum in your network can reach them through the YC community.
Their group partner at YC was Jared Friedman, YC Group Partner — the partner who ran Talus Bio's batch and knows the company first-hand. YC profile ↗
In turn, Omri can intro founders to Talus Bio's investors below.
Talus Bio's investors · 9
Co-founders at Talus Bio
Experience
- EarthTraq CorporationBoard Membercurrent2026 — present
- PortalBoard Membercurrent2026 — present
- Cyclana BioBoard Membercurrent2025 — present
- ImmuneBridgeBoard Membercurrent2025 — present
- Powerhouse BiologyBoard Membercurrent2025 — present
- Permanence BioBoard Membercurrent2025 — present
- Radar TherapeuticsBoard Membercurrent2024 — presentSan Francisco Bay Area
- TwoStep TherapeuticsBoard Membercurrent2024 — presentSan Francisco Bay Area
- ZipBioBoard Membercurrent2023 — present
- CentivaxBoard Membercurrent2022 — present
- Renewal BioFounder & chairman of the boardcurrent2022 — presentRehovot, Center District, Israel
- PumpkinseedBoard Membercurrent2022 — present
- Talus BioBoard Membercurrent2021 — present
- Mana.bioBoard Membercurrent2021 — present
- Nanocarry TherapeuticsBoard Membercurrent2021 — present
- NFXGeneral Partnercurrent2020 — present
- Eleven TherapeuticsBoard Membercurrent2020 — present
- EdiTy TherapeuticsBoard Membercurrent2020 — present
- ImmunaiAdvisorcurrent2020 — present
- Light Bio, Inc.Board Membercurrent2020 — present
- 8400 - The Health NetworkMembercurrent2020 — present
- tech.bioFounding Partnercurrent2018 — present
- Mammoth BiosciencesAdvisorcurrent2016 — presentSan Francisco Bay Area
- IndieBioMentorcurrent2015 — presentSan Francisco Bay Area
- PsygaBioBoard Member2021 — 2026
- La Jolla LabsBoard Member2021 — 2026San Diego Metropolitan Area
- PANGEA TherapeuticsBoard Member2021 — 2026
- Pepper BioBoard Member2021 — 2025
- Gilboa TherapeuticsBoard Member2021 — 2024
- resistanceBioBoard Member2022 — 2024
- C2i GenomicsBoard Observer2019 — 2024
- AGE1Mentor2019 — 2023
- Loop GenomicsAdvisor2015 — 2022San Francisco Bay Area
- Wild BiotechBoard Member2019 — 2022
- Armada BiosystemsBoard Member2019 — 2021
- Twist BioscienceHead of Corporate Development2016 — 2018San Francisco Bay Area
- Singularity UniversityIsraeli Community Ambassador2015 — 2016Tel-Aviv
- Genome Compiler Corp. Acquired by Twist BioscienceFounder & CEO2011 — 2016San Francisco Bay Area
- Stanford University school of medicinePostdoctoral associate2007 — 2011
- Singularity Universityattendee2011
Skills & more
+12 more
DNATechnology TransferPersonalized MedicineBiomedical EngineeringPCRCancerScientific WritingProtein ExpressionBiophysicsProteomicsDrug DiscoveryIn VitroFrom Omri's professional profile.
Deals · 5
TwoStep TherapeuticsBoard seat
via NFX · filed Jan 2026 · $62.2M raise
ImmuneBridgeBoard seat
via NFX · filed Apr 2025 · $7.1M raise
ResistanceBioBoard seat
via NFX · filed Jan 2024 · $12.8M raise
La Jolla LabsBoard seat
via NFX · filed Oct 2021 · $3.5M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at NFX
Network4
Investors connected to Omri in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Omri Amirav Drory?
- Omri Amirav-Drory is a founder-operator with TechBio lifecycle experience—founding Genome Compiler (acquired by Twist Bioscience), serving as Twist VP of Corporate Development and Innovation and acting as CEO during incubation.
- Where does Omri Amirav Drory work?
- Omri Amirav Drory is General Partner at NFX and Board director at TwoStep Therapeutics and Board director at ImmuneBridge and Board director at Talus Bio.
- What does Omri Amirav Drory invest in?
- Omri Amirav Drory invests in AI & Machine Learning, Biotech, Crypto & Web3, Fintech, Marketplaces.
- What check size does Omri Amirav Drory write?
- Omri Amirav Drory typically writes checks of $500K – $5M.
- What boards does Omri Amirav Drory sit on?
- Omri Amirav Drory holds tracked board seats at ImmuneBridge, La Jolla Labs, ResistanceBio, Talus Bio, TwoStep Therapeutics.
- Where did Omri Amirav Drory go to school?
- Omri Amirav Drory studied at Stanford University (Postdoctoral, Biochemistry and Molecular Biology); Tel Aviv University (Doctor of Philosophy (Ph.D.), Biochemistry); Tel Aviv University (Bachelor of Science - BS, Biochemistry and Molecular Biology).
Founder mafias
Stanford University mafia903
Also came through, then founded or led a company.
+ 896 more
Tel Aviv University mafia60
Also came through, then founded or led a company.
+ 53 more
NFX mafia10
Also came through, then founded or led a company.
+ 3 more
Immunai mafia3
Also came through, then founded or led a company.
Twist Bioscience mafia3
Also came through, then founded or led a company.
Same school
Also attended Stanford University2,000
+ 1,994 more
Also attended Tel Aviv University412
+ 406 more





































































